Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France

IMPORTANCE: Risk of developing progressive multifocal leukoencephalopathy (PML) is the major barrier to using natalizumab for patients with multiple sclerosis (MS). To date, the association of risk stratification with PML incidence has not been evaluated. OBJECTIVE: To describe the temporal evolutio...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:JAMA Neurol
المؤلفون الرئيسيون: Vukusic, Sandra, Rollot, Fabien, Casey, Romain, Pique, Julie, Marignier, Romain, Mathey, Guillaume, Edan, Gilles, Brassat, David, Ruet, Aurélie, De Sèze, Jérôme, Maillart, Elisabeth, Zéphir, Hélène, Labauge, Pierre, Derache, Nathalie, Lebrun-Frenay, Christine, Moreau, Thibault, Wiertlewski, Sandrine, Berger, Eric, Moisset, Xavier, Rico-Lamy, Audrey, Stankoff, Bruno, Bensa, Caroline, Thouvenot, Eric, Heinzlef, Olivier, Al-Khedr, Abdullatif, Bourre, Bertrand, Vaillant, Mathieu, Cabre, Philippe, Montcuquet, Alexis, Wahab, Abir, Camdessanché, Jean-Philippe, Tourbah, Ayman, Guennoc, Anne-Marie, Hankiewicz, Karolina, Patry, Ivania, Nifle, Chantal, Maubeuge, Nicolas, Labeyrie, Céline, Vermersch, Patrick, Laplaud, David-Axel
التنسيق: Artigo
اللغة:Inglês
منشور في: American Medical Association 2019
الموضوعات:
Original Investigation
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC6724170/
https://ncbi.nlm.nih.gov/pubmed/31479149
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2019.2670
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة